Series B · Medtech & Devices · Dublin, Ireland · Founded 2014 · 60–83 employees
FIRE1 develops the NORM system, an implantable heart failure monitoring device that measures fluid volume directly rather than relying on proxies. The device consists of a sensor placed in the inferior vena cava, a belt worn for minutes daily, and an app for data access. Recently raised $120 million in Series B funding to complete pivotal clinical trials across Europe and the US. The company has FDA Breakthrough Device Designation and aims for FDA approval by 2029, positioning to transform heart failure management for 64 million patients worldwide.